Medical Access and Reimbursement in Costa Rica

Currently classified as a strictly controlled psychotropic/illicit substance under Costa Rica's Ley Nº 8204 framework, which implements the UN drug conventions and authorizes the Ministry of Health to list and regulate controlled psychotropics; there is no authorized medical reimbursement or routine clinical access outside of approved, formally registered research. #.

Currently classified as a strictly controlled psychotropic/illicit substance under Costa Rica's national drug law (Ley Nº 8204) with no routine medical reimbursement or authorized clinical use outside approved research trials. Any therapeutic use would require participation in an approved clinical study or specific sanitary registration by the Ministerio de Salud. #.

Esketamine (the intranasal product marketed internationally as Spravato) is not widely documented as part of a public, nationally reimbursed mental-health program in Costa Rica; there is limited signal in pharmacovigilance and case-report literature showing exposures/uses reported from Costa Rica, but no clear public record of a national reimbursement program or routine inclusion in the Caja Costarricense de Seguro Social formularies. Use of esketamine-equivalent treatments in Costa Rica would be constrained to licensed prescribers, specialty clinics and private-sector arrangements rather than broad public-insurance reimbursement. (See pharmacovigilance/case reports including Costa Rican cases). #.

Because esketamine products require specific regulatory approval/market authorization to be publicly reimbursed and to be dispensed in specialty REMS-like frameworks elsewhere, clinicians in Costa Rica seeking esketamine would generally need national sanitary registration/authorization through the Ministerio de Salud or importation under authorized medical supply rules; there is no publicly documented national Spravato reimbursement listing available in Costa Rican government publications as of searches. #.

Ketamine is a registered anesthetic and medical drug in Costa Rica and is used within conventional medical practice (anesthesia, emergency medicine) and increasingly in private psychiatric/infusion-clinic settings for off‑label treatment of depression, PTSD and other indications. Costa Rica's forensic and judicial services list ketamine among substances they identify in seized materials and medical settings, confirming its regulated status as a controlled medicine when used medically. #.

In practice: private clinics and international medical‑tourism providers advertise ketamine infusion therapy and ketamine-assisted programs in Costa Rica; these programs operate predominantly in the private sector (out‑of‑pocket payment) rather than as a covered benefit under universal public reimbursement. Multiple clinic directories and industry reports describe IV/IM/sublingual ketamine services offered to domestic and international patients; such treatments are typically prescribed and administered by licensed physicians but are not part of a nationally standardized, publicly reimbursed mental‑health pathway. #, #.

Regulatory nuance: while ketamine itself is medically authorized and available through licensed health professionals, structured reimbursement for ketamine as an antidepressant (off‑label) is not documented as a routine benefit of the Caja Costarricense de Seguro Social; payments for ketamine‑infusion therapy in Costa Rica are therefore commonly private/self‑pay or part of private insurance arrangements when accepted by insurers.

DMT (N,N‑dimethyltryptamine) is treated as a controlled psychotropic substance under the national law implementing UN conventions (Ley Nº 8204) and therefore has no authorized medical reimbursement outside approved research. While plant‑based ayahuasca ceremonies (containing DMT) do occur in Costa Rica in retreat settings, those activities exist in a legal gray zone and are not the same as nationally sanctioned medical access or reimbursement. Any lawful therapeutic use would require formal research authorization or explicit sanitary registration. #.

Currently classified as a strictly controlled substance under Costa Rican drug‑control law (Ley Nº 8204) with no authorized medical use or reimbursement outside of approved clinical trials or tightly controlled research. Retreats using natural 5‑MeO‑DMT sources may exist informally, but this does not equate to legal, reimbursed medical access. #.

Ibogaine occupies a practical regulatory gray zone in Costa Rica: it is not widely scheduled in the same explicit way some other countries schedule it, and several private clinics catering to international patients offer ibogaine treatment in Costa Rica; however, those services typically operate without formal sanitary registration or a clear national reimbursement pathway and have attracted public‑health warnings. The Ministry of Health has not established a nationally recognized, reimbursed ibogaine treatment program; clinics operate largely in the private sector and may be unregulated or variably regulated locally. For example, international clinic listings and medical‑tourism literature report ibogaine offerings in Costa Rica while warning of lack of formal government authorization; some health‑advisory pages note Ministry of Health warnings about advertising/use without sanitary registration. #, #.

Because ibogaine treatments in Costa Rica are typically private, out‑of‑pocket, and not reimbursed by the national health service, clinical access is effectively limited to private clinics or research protocols rather than any public insurance coverage.

Ayahuasca (a plant brew containing DMT) is legally complicated in Costa Rica: while DMT is a controlled psychotropic under the national law derived from UN conventions, there are retreat centers and ceremonial practitioners who offer ayahuasca ceremonies in Costa Rica. Those activities operate largely in an informal/private/ceremonial context and are not the same as a sanctioned, reimbursed medical treatment. Any medically authorized use would require explicit sanitary registration and oversight by the Ministerio de Salud or inclusion in an approved clinical trial. Guidance for international patients emphasizes that ayahuasca retreats are not covered by public reimbursement and carry variable levels of clinical oversight. #, #.

Mescaline (and mescaline‑containing preparations intended for human consumption) is regulated under the national drug framework (Ley Nº 8204) and treated as a controlled psychotropic/illicit substance; there is no national medical reimbursement pathway for mescaline and no routine authorized clinical use outside research. While some cacti that contain mescaline may be sold in plant/ornamental markets elsewhere, extraction or psychoactive use is controlled and illegal for non‑authorized purposes per the national law. #.

The 2C‑family (e.g., 2C‑B and related substituted phenethylamines) falls under the national controlled‑substances framework; these are treated as illicit psychotropic/controlled substances under Ley Nº 8204 and have no authorized medical reimbursement or routine clinical use outside approved research. Possession, distribution or manufacture for non‑authorized purposes is criminalized. #.